IGI Logo

Aurobindo Pharma is currently trading at Rs. 1004.05, up by 14.65 points or 1.48% from its previous closing of Rs. 989.40 on the BSE.

The scrip opened at Rs. 1006.45 and has touched a high and low of Rs. 1013.90 and Rs. 996.00 respectively. So far 8516 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1177.00 on 30-Jan-2024 and a 52 week low of Rs. 466.00 on 21-Mar-2023.

Last one week high and low of the scrip stood at Rs. 1022.35 and Rs. 985.05 respectively. The current market cap of the company is Rs. 57972.77 crore.

The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 41.32% and 6.85% respectively.

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Mometasone Furoate Monohydrate Nasal Spray, 50 mcg/spray, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Nasonex Nasal Spray, 50 mcg/spray of Organon LLC. The product will be launched in Q1FY25.

The approved product has an estimated market size of $44.5 million for the twelve months ending January 2024, according to IQVIA. Aurobindo now has a total of 507 ANDA approvals (488 Final approvals and 19 tentative approvals) from USFDA.

Mometasone Furoate Monohydrate Nasal Spray, 50 mcg/spray, is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis, in adults and paediatric patients 2 years of age and older.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.